Celldex Therapeutics (CLDX) Other Working Capital Changes (2010 - 2026)

Celldex Therapeutics' Other Working Capital Changes history runs 17 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• On a quarterly basis, Other Working Capital Changes rose 213.6% year-over-year to $2.1 million in Q1 2026; TTM through Mar 2026 was $5.0 million, a 22.77% increase from a year earlier, with the FY2025 full-year figure at $3.6 million, down 62.54% from the prior year.
• Other Working Capital Changes slipped to $2.1 million in Q1 2026 per CLDX's latest filing, from $4.0 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $7.1 million in Q1 2022 and bottomed at -$4.1 million in Q4 2023.
• The 5-year median for Other Working Capital Changes is $999500.0 (2022), against an average of $1.2 million.
• Across the five-year window, Other Working Capital Changes surged 521.54% in 2022 and tumbled 352.01% in 2023, its largest moves.
• Year by year, Other Working Capital Changes stood at $1.6 million in 2022, then slumped by 352.01% to -$4.1 million in 2023, then jumped by 197.27% to $4.0 million in 2024, then declined by 0.89% to $4.0 million in 2025, then tumbled by 48.02% to $2.1 million in 2026.
• Per Business Quant, the three latest CLDX Other Working Capital Changes figures stand at $2.1 million (Q1 2026), $4.0 million (Q4 2025), and $64000.0 (Q3 2025).